1. Introduction to Proto Oncogenes

  1.1 Overview

  1.2 Discovery of Transmissible Cancer Gene

  1.3 Products of Oncogenes

2. Activation of Proto Oncogene to Oncogenes

  2.1 From Proto Oncogenes to Oncogenes

    2.1.1 Gene Amplification

    2.1.2 Chromosomal Translocation

    2.1.3 Mutations

  2.2 Hallmarks of Cancer

3. Oncogenes as Therapeutic Targets for Treatment

  3.1 ERBB2 as a Target for Breast Cancer Therapy

  3.2 EGFR as a Target for Colorectal Cancer Therapy

  3.3 VEGF as a Target for Non-Small Cell Lung Cancer

  3.4 PDGFR as a Target for Renal Cell Carcinoma

4. Prognostic and Predictive Role of Oncogenes

  4.1 HER2

  4.2 BRAF V600E

  4.3 BCL-2

  4.4 SRC

5. Market Analysis of Proto Oncogene Therapeutic Drugs

  5.1 Axitinib (Inlyta)

  5.2 Ponatinib (Iclusig)

  5.3 Imatinib (Gleevec)

  5.4 Sunitinib (Sutent)

  5.5 Pazopanib (Votrient)

  5.6 Dabrafenib (Tafinlar)

  5.7 Vandetanib (Caprelsa)

  5.8 Vemurafenib (Zelboraf)

  5.9 Cabozantinib (Cabometyx and Cometriq)

  5.10 Sorafenib (Nexavar)

6. Market Introduction of Proto Oncogenes

  6.1 Overview

  6.2 Global Sales of Proto-Oncogene Drugs

  6.3 Global Proto Oncogene Protein Inhibitors Pipeline Overview

7. Global Proto Oncogene Market Dynamics

  7.1 Favorable Market Parameters

  7.2 Commercialization Challenges

8. Future Perspective of Proto Oncogene Market

9. Global Proto-Oncogene Protein Inhibitors Clinical Pipeline by Company, Indication and Phase

  9.1 Research

  9.2 Preclinical

  9.3 Clinical

  9.4 Phase-I

  9.5 Phase-I/II

  9.6 Phase-II

  9.7 Phase-III

  9.8 Preregistration

  9.9 Registered

10. Marketed Global Proto-Oncogene Protein Inhibitors Clinical Insight by Company and Indication

  10.1 Axitinib (Inlyta)

  10.2 Ponatinib (Iclusig)

  10.3 Imatinib (Gleevec, Glivec and Ruvise)

  10.4 Lenvatinib (Kisplyx and Lenvima)

  10.5 Sunitinib (Sutent)

  10.6 Pazopanib (Votrient)

  10.7 Dabrafenib (Tafinlar)

  10.8 Vandetanib (Caprelsa, Zactima and Zictifa)

  10.9 Vemurafenib (Zelboraf)

  10.10 Cabozantinib (Cabometyx and Cometriq)

  10.11 Nilotinib (Tasigna)

  10.12 Regorafenib (Stivarga)

  10.13 Dasatinib (Sprycel)

  10.14 Sorafenib (Nexavar)

  10.15 Crizotinib (Xalkori)

  10.16 Apatinib

  10.17 Omacetaxine Mepesuccinate (Synribo)

  10.18 Imatinib - Pharm-Sintez (Imatib)

  10.19 Phaleria Macrocarpa extract (Phalecarps)

11. Competitive Landscape

  11.1 ARIAD Pharmaceuticals

  11.2 AstraZeneca

  11.3 Bayer Healthcare

  11.4 Bristol-Myers Squibb

  11.5 ChemGenex Pharmaceuticals

  11.6 Dexa Medica

  11.7 Eisai Pharmaceuticals

  11.8 Exelixis

  11.9 GlaxoSmithKline

  11.10 Novartis

  11.11 Onyx Pharmaceuticals

  11.12 Plexxikon

  11.13 Pfizer

Figure 1-1: Historical Development of Oncogenes in Various Cancer Cell Lines

Figure 1-2: Organization of the Proto Oncogene Products

Figure 2-1: Activation Methods of Oncogenes from Proto Oncogenes

Figure 2-2: Gene Amplification Step in the Conversion of Proto Oncogenes to Oncogenes

Figure 2-3: Chromosomal Translocation for the Activation Oncogene from Proto Oncogene

Figure 2-4: Classification of the Hallmarks of Cancer

Figure 3-1: Role of VEGF as a Target to Non-Small Cell Lung Cancer

Figure 3-2: PDGFR Target for the Treatment of Renal Cell Carcinoma

Figure 5-1: Axitinib- Patent Approval and Expiration Year in US

Figure 5-2: Axitinib- Patent Approval and Expiration Year in Europe

Figure 5-3: Axitinib Dosage Analysis (mg/Day)

Figure 5-4: Available Concentrations of Axitinib Oral Tablet (mg)

Figure 5-5: Inlyta- Price Analysis by Concentration (US$/Unit), 2018

Figure 5-6: Axitinib Price Analysis US$/Packet), 2018

Figure 5-7: Axitinib Treatment Cost (US$/Cycle), 2017

Figure 5-8: Ponatinib- Patent Approval Year and Expiration Year in US

Figure 5-9: Ponatinib- Patent Approval Year and Expiration Year in Europe

Figure 5-10: Iclusig Dosage Analysis (mg/Day)

Figure 5-11: Available Concentrations of Iclusig Oral Tablet Drug, mg

Figure 5-12: Iclusig- Price Analysis (US$), 2017

Figure 5-13: Imatinib- Patent Approval Year and Patent Expiration Year in US

Figure 5-14: Imatinib- Patent Approval Year and Patent Expiration Year in Europe

Figure 5-15: Imatinib Price Analysis by Concentration (US$/Unit), 2017

Figure 5-16: Imatinib Price Analysis by Concentration (US$/Packet), 2017

Figure 5-17: Sunitinib- Patent Approval Year and Expiration Year in US

Figure 5-18: Sunitinib- Patent Approval Year and Expiration Year in Europe

Figure 5-19: Available Concentrations of Sunitinib Drug, mg

Figure 5-20: Sutent Capsule Price by Concentration (US$/Unit), 2017

Figure 5-21: Sunitinib- Price Analysis by Concentration (US$/Packet), 2017

Figure 5-22: Pazopanib- Patent Approval Year and Patent Expiration Year in US

Figure 5-23: Pazopanib- Patent Approval Year and Patent Expiration Year in Europe

Figure 5-24: Pazopanib Dosage Analysis (mg/Day)

Figure 5-25: Pazopanib Price Analysis by Quantity (US$), 2017

Figure 5-26: Dabrafenib- Patent Approval and Expiration Year in US

Figure 5-27: Dabrafenib- Patent Approval and Expiration Year in Europe

Figure 5-28: Dabrafenib Dosage Analysis (mg/Day)

Figure 5-29: Available Concentration of Dabrafenib Drug, mg

Figure 5-30: Dabrafenib Price Analysis by Concentration (US$/Unit), 2017

Figure 5-31: Tafinlar Capsule Average Price Analysis by Concentration (US$/120 Capsules), 2017

Figure 5-32: Vandetanib- Patent Approval and Expiration Year in US

Figure 5-33: Vandetanib- Patent Approval and Expiration Year in Europe

Figure 5-34: Vandetanib Dosage Analysis (mg/Day)

Figure 5-35: Available Concentrations of Vandetanib Drug, mg

Figure 5-36: Vandetanib Price Analysis (US$/Unit), 2017

Figure 5-37: Vandetanib- Drug Cost (US$) in Concentration of 100 mg and 300 mg for 30 Tablets, 2017

Figure 5-38: Vemurafenib- Patent Approval Year and Expiration Year in US and Europe

Figure 5-39: Vemurafenib- Patent Approval Year and Expiration Year in Europe

Figure 5-40: Vemurafenib Dosage Analysis (mg/Day)

Figure 5-41: Vemurafenib- Market Cost of Drug (US$) for 112 Tablets and Per Unit Cost, 2017

Figure 5-42: Cabozantinib- Patent Approval Year and Expiration Year in US

Figure 5-43: Cabozantinib- Patent Approval Year and Expiration Year in Europe

Figure 5-44: Cabozantinib Dosage Analysis (mg/Day)

Figure 5-45: Available Concentrations of Cabozantinib Oral Tablet, mg

Figure 5-46: Available Drug Concentrations of Cometriq Oral Capsule, mg

Figure 5-47: Cabozantinib- Drug Cost of 20mg Concentration (US$) for 30 Tablets and Per Unit Dose, 2017

Figure 5-48: Cost of Cometriq Capsules for the Supply of 50 Capsules of Different Concentrations, (US$)

Figure 5-49: Sorafenib- Patent Approval Year and Expiration Year in US

Figure 5-50: Sorafenib- Patent Approval Year and Expiration Year in Europe

Figure 5-51: Sorafenib- Drug Cost for 120 Tablets and Per Unit Dose (US$), 2017

Figure 6-1: Global- Axitinib Drug Sales (US$ Million), 2015 and 2016

Figure 6-2: Iclusig - Sales (US$ Million), 2015

Figure 6-3: Iclusig - Sales (US$), 2016 and 2017

Figure 6-4: Global- Sales Revenue of Sunitinib Drug (US$ Billion), 2015 and 2016

Figure 6-5: Global- Sales of Pazopanib Drug (US$ Million), 2015 and 2016

Figure 6-6: Global- Sales Revenue of Vemurafenib Drug (US$ Million), 2015 and 2016

Figure 6-7: Global- Sales of Imatinib (US$ Billion), 2014-2017

Figure 6-8: Global Sales of Dabrafenib Drug (US$ Million), 2015 and 2016

Figure 6-9: Global Sales Revenue of Sorafenib Drug (US$ Million), 2014-2016

Figure 6-10: Cabozantinib (Cabometyx and Cometriq) – Sales (US$ Million), 2016 and 2017*

Figure 6-11: Cabometyx and Cometriq – Sales (US$ Million), 2016 and 2017*

Figure 6-12: Global Proto Oncogene Protein Inhibitors Clinical Pipeline by Phase (%), 2017 till 2024

Figure 6-13: Global Proto-Oncogene Protein Inhibitors Clinical Pipeline by Phase (Number), 2017 till 2024

Figure 7-1: Favorable Factors which Promote the Market Growth of Proto Oncogenes

Figure 7-2: Challenges to the Market Growth of Proto Oncogenes

Figure 8-1: Frontiers for the Inhibition of Cancer Development by Active Oncogenes

Table 3-1: Possible Ways to Overcome ErBb2 Mediated Chemoresistance

Table 3-2: Components of EGFR Signaling Pathway Important in Colorectal Cancer

Table 4-1: Role of Cancer Oncogene as Predictive and Prognostic Biomarker

Table 5-1: Imatinib Dosage for Various Indications (mg/Day and mg/m2/Day)

Table 5-2: Cost Effective Analysis of Imatinib Drug

Table 5-3: Clinical Efficacy Results of Sunitinib Drug in Cancer Treatment

Table 5-4: Clinical Efficacy Results of Pazopanib Drug in Cancer Treatment

Table 5-5: Clinical Effective Analysis of Dabrafenib Drug

Table 5-6: Clinical Effective Analysis of Vandetanib Drug

Table 5-7: Clinical Efficacy of Vemurafenib Drug in Cancer Treatment